chr19-11105586-ACGAGGAAAACTG-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM4PP3PP5_Very_Strong
The NM_000527.5(LDLR):c.683_694delAGGAAAACTGCG(p.Glu228_Cys231del) variant causes a disruptive inframe deletion, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
LDLR
NM_000527.5 disruptive_inframe_deletion, splice_region
NM_000527.5 disruptive_inframe_deletion, splice_region
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 9.88
Genes affected
LDLR (HGNC:6547): (low density lipoprotein receptor) The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
In a helix (size 2) in uniprot entity LDLR_HUMAN there are 16 pathogenic changes around while only 0 benign (100%) in NM_000527.5
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_000527.5.
PP3
No computational evidence supports a deleterious effect, but strongly conserved according to phyloP
PP5
Variant 19-11105586-ACGAGGAAAACTG-A is Pathogenic according to our data. Variant chr19-11105586-ACGAGGAAAACTG-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 403633.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.683_694delAGGAAAACTGCG | p.Glu228_Cys231del | disruptive_inframe_deletion, splice_region_variant | 4/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.683_694delAGGAAAACTGCG | p.Glu228_Cys231del | disruptive_inframe_deletion, splice_region_variant | 4/18 | 1 | NM_000527.5 | ENSP00000454071.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation | Nov 05, 2016 | Disrupt SDE motif. SDE bind structural Ca2+. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2018 | The c.683_694del12 variant (also known as p.E228_C231del) is located in coding exon 4 of the LDLR gene. This variant results from an in-frame AGGAAAACTGCG deletion at nucleotide positions 683 to 694 at the end of exon 4. This results in the deletion of four amino acids between codons 228 and 231. This alteration has been reported in a cohort of subjects with familial hypercholesterolemia (Tichý L et al. Physiol Res, 2017 Apr;66:S47-S54). In addition, internal structural analysis indicates that this alteration both alters the conserved SDE triplet motif and disrupts a disulfide bond in the LDL type A repeat 5, which is important for ligand binding (Ambry internal data). Based on four different splice site prediction tools, this alteration is expected to create an in-frame alternate splice donor site at the new exon-intron boundary created by the deletion; however, experimental evidence is not currently available. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Familial hypercholesterolemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 21, 2017 | This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a LDLR-related disease. For these reasons, this variant has been classified as Pathogenic. At least two different substitutions within this deleted sequence (p.Gln228Gln and p.Cys231Gly) have been determined to be pathogenic (PMID: 8882879, 16250003, 17094996, 8664907). This suggests that several residues within this region are critical for LDLR protein function. Algorithms developed to predict the effect of sequence changes on mRNA splicing suggest that this variant may alter RNA splicing, but this prediction has not been confirmed by published transcriptional studies. This sequence change deletes 12 nucleotides from exon 4 of the LDLR mRNA (c.683_694delAGGAAAACTGCG). This leads to the deletion of 4 amino acid residues in the LDLR protein (p.Glu228_Cys231del) but otherwise preserves the integrity of the reading frame. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at